Page 1

EMERGENT BIOSOLUTIONS REPORTS FINANCIAL RESULTS FOR THIRD QUARTER 2021 GAITHERSBURG , Md . , November 4 , 2021 - Emergent BioSolutions Inc. ( NYSE : EBS ) today reported financial results for the third quarter ended September 30 , 2021 . " Emergent's core products and service businesses remain strong as evidenced by our accomplishments this quarter , " said Robert G. Kramer , president and CEO of Emergent BioSolutions . " We have secured renewals of multiple medical countermeasure supply contracts , made pipeline advancements , implemented organizational enhancements that better serve our customers , and are pursuing new business prospects . We are confident in our 2024 growth plan and remain focused on our mission - to protect and enhance life . " FINANCIAL HIGHLIGHTS ( 1 ) ( $ in millions , except per share amounts ) Total revenues Net ( loss ) income Net ( loss ) income per diluted share Adjusted net ( loss ) income ( 2 ) Adjusted net ( loss ) income ( 2 ) per diluted share Adjusted EBITDA ( 2 ) ( $ in millions , except per share amounts ) Total revenues Net income Net income per diluted share Adjusted net income ( 2 ) Adjusted net income ( 2 ) per diluted share Adjusted EBITDA ( 2 ) * % change is greater than 100 % emergent biosolutions® Q3 2021 $ 329.0 ( $ 32.7 ) ( $ 0.61 ) ( $ 19.3 ) ( $ 0.36 ) ( $ 3.3 ) YTD 2021 $ 1,069.5 $ 41.6 $ 0.77 $ 82.3 $ 1.52 $ 169.7 Q3 2020 $ 385.2 $ 39.5 $ 0.73 $ 119.0 $ 2.19 $ 168.1 YTD 2020 $ 972.4 $ 119.7 $ 2.23 $ 225.1 $ 4.20 $ 339.5 % Change ( 15 ) % * % Change 10 % ( 65 ) % ( 65 ) % ( 63 ) % ( 64 ) % ( 50 ) % Q3 2021 AND OTHER RECENT BUSINESS Announced a mutual agreement with the U.S. Department of Health and Human Services ( HHS ) to terminate the Company's 2012 Center for Innovation in Advanced Development and Manufacturing ( CIADM ) contract to establish a public - private partnership for pandemic preparedness , along with all associated task orders , including the 2020 task order to reserve capacity and expand manufacturing for third - party COVID - 19 vaccine and therapeutic candidates Initiated a pivotal Phase 3 safety and immunogenicity study to evaluate CHIKV VLP , the company's single - dose chikungunya virus virus - like particle vaccine candidate Secured a multi - year development and manufacturing agreement with Providence Therapeutics , valued at approximately $ 90 million , for its mRNA COVID - 19 vaccine candidate Received a contract modification to the 2016 AV7909 ( Anthrax Vaccine Adsorbed with Adjuvant ) development and procurement contract with the U.S. government , valued at approximately $ 399 million , to deliver doses of AV7909 to the Strategic National Stockpile ( SNS ) over 18 months Received Orphan Drug designation from the U.S. Food and Drug Administration ( FDA ) for AV7909 1 of 16